These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 29650343)

  • 1. Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension.
    Levy M; Del Cerro MJ; Nadaud S; Vadlamudi K; Colgazier E; Fineman J; Bonnet D; Adatia I
    Int J Cardiol; 2018 Aug; 264():153-157. PubMed ID: 29650343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
    Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA
    J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
    Ivy DD; Claussen L; Doran A
    Am J Cardiol; 2007 Mar; 99(5):696-8. PubMed ID: 17317374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of subcutaneous treprostinil in pediatric pulmonary arterial hypertension-Bridge-to-transplant or long-term treatment?
    Ablonczy L; Tordas D; Kis E; Szatmári A
    Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29266571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil.
    Kurzyna M; Małaczyńska-Rajpold K; Koteja A; Pawlak A; Chrzanowski Ł; Furdal M; Gąsior Z; Jacheć W; Sobkowicz B; Norwa J; Mularek-Kubzdela T; Torbicki A
    BMC Pulm Med; 2017 Dec; 17(1):162. PubMed ID: 29195500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension.
    Kimmig LM; Liao C; Bag R
    Lung; 2020 Feb; 198(1):53-58. PubMed ID: 31912412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial.
    Sadushi-Kolici R; Jansa P; Kopec G; Torbicki A; Skoro-Sajer N; Campean IA; Halank M; Simkova I; Karlocai K; Steringer-Mascherbauer R; Samarzija M; Salobir B; Klepetko W; Lindner J; Lang IM
    Lancet Respir Med; 2019 Mar; 7(3):239-248. PubMed ID: 30477763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
    Mathier MA; McDevitt S; Saggar R
    J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
    Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB
    Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan.
    Benza RL; Rayburn BK; Tallaj JA; Pamboukian SV; Bourge RC
    Chest; 2008 Jul; 134(1):139-45. PubMed ID: 18403673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension.
    Skoro-Sajer N; Gerges C; Balint OH; Kohalmi D; Kaldararova M; Simkova I; Jakowitsch J; Gabriel H; Baumgartner H; Gerges M; Sadushi-Kolici R; Celermajer DS; Lang IM
    Heart; 2018 Jul; 104(14):1195-1199. PubMed ID: 29436381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Treprostinil in Pediatric Pulmonary Hypertension: Case Reports and Review of the Literature.
    Gavotto A; Thomas F; Werner O; Moreau J; Amedro P
    J Cardiovasc Pharmacol; 2020 Jul; 76(1):23-31. PubMed ID: 32168152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, Tolerability and Clinical Effects of a Rapid Dose Titration of Subcutaneous Treprostinil Therapy in Pulmonary Arterial Hypertension: A Prospective Multi-Centre Trial.
    Grünig E; Benjamin N; Lange TJ; Krueger U; Klose H; Neurohr C; Wilkens H; Halank M; Seyfarth HJ; Held M; Traube A; Pernow M; Grover ER; Egenlauf B; Gerhardt F; Viethen T; Rosenkranz S
    Respiration; 2016; 92(6):362-370. PubMed ID: 27784026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
    Frantz RP; McDevitt S; Walker S
    J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
    Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
    Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.